Lopinavir/Ritonavir + 2 NRTIs — Competitive Intelligence Brief

Lopinavir/Ritonavir + 2 NRTIs (Lopinavir/Ritonavir + 2 NRTIs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Lopinavir/Ritonavir + 2 NRTIs (Lopinavir/Ritonavir + 2 NRTIs) — National Institute of Allergy and Infectious Diseases (NIAID). Lopinavir/ritonavir inhibits HIV protease to prevent viral maturation, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block viral RNA replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/Ritonavir + 2 NRTIs TARGET	Lopinavir/Ritonavir + 2 NRTIs	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Bristol-Myers Squibb · 3 drugs in this class
2. Juan A. Arnaiz · 2 drugs in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class
5. University of Cologne · 1 drug in this class
6. Amsterdam UMC, location VUmc · 1 drug in this class
7. ViiV Healthcare · 1 drug in this class
8. Drugs for Neglected Diseases · 1 drug in this class